INT26860

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.41
First Reported 1989
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 7
Total Number 9
Disease Relevance 3.21
Pain Relevance 1.18

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
liver 2
blood 1
ileum 1
sweats 1
neural 1
Vms1 (Mus musculus)
Pain Link Frequency Relevance Heat
transdermal 63 98.64 Very High Very High Very High
Enkephalin 7 98.58 Very High Very High Very High
MU agonist 1 97.78 Very High Very High Very High
narcan 2 96.68 Very High Very High Very High
Gabapentin 1 84.32 Quite High
sSRI 1 83.36 Quite High
Clonidine 1 73.92 Quite High
imagery 2 65.76 Quite High
anesthesia 4 58.84 Quite High
headache 6 55.44 Quite High
Disease Link Frequency Relevance Heat
Osteoporosis 3 100.00 Very High Very High Very High
Osteoporotic Fractures 3 100.00 Very High Very High Very High
Endometriosis (extended) 37 99.62 Very High Very High Very High
Hot Flashes 57 99.44 Very High Very High Very High
Pressure And Volume Under Development 2 98.74 Very High Very High Very High
Reprotox - General 3 6 95.40 Very High Very High Very High
Cancer 6 95.08 Very High Very High Very High
Reprotox - General 1 6 94.24 High High
Coagulation Disorder 3 92.52 High High
Hypertension 3 91.52 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Although most women will experience an abatement of their VMS by 5 years after their final menses, women with early or surgical menopause may have worse or more persistent symptoms, and up to 16% of naturally menopausal women continue to experience VMS well after their menopause is past.
Positive_regulation (experience) of VMS associated with endometriosis (extended)
1) Confidence 0.41 Published 2008 Journal Clin Obstet Gynecol Section Abstract Doc Link 18677148 Disease Relevance 0.37 Pain Relevance 0.20
We conclude that phenylephrine-induced baroreceptor stimulation elicits divergent VMS activity responses in developing and mature animals.
Positive_regulation (elicits) of VMS
2) Confidence 0.38 Published 1995 Journal Dev. Neurosci. Section Abstract Doc Link 8575343 Disease Relevance 0 Pain Relevance 0.03
In contrast to adult cats, 10-day kittens increased VMS neural activity in a dose-dependent fashion with pressor stimulation.
Positive_regulation (increased) of VMS in neural
3) Confidence 0.38 Published 1995 Journal Dev. Neurosci. Section Abstract Doc Link 8575343 Disease Relevance 0 Pain Relevance 0.09
Phenylephrine elevated blood pressure and elicited an initial VMS activity decline and a subsequent rise in VMS activity in all states, although the initial decline during quiet sleep occurred only in rostral placements.
Positive_regulation (rise) of VMS in blood associated with pressure and volume under development
4) Confidence 0.31 Published 2000 Journal Am. J. Physiol. Regul. Integr. Comp. Physiol. Section Abstract Doc Link 10749799 Disease Relevance 0.10 Pain Relevance 0
A sodium nitroprusside depressor challenge increased VMS activity more in REM sleep than in quiet sleep, with the increase being even less in waking.
Positive_regulation (increased) of VMS
5) Confidence 0.31 Published 2000 Journal Am. J. Physiol. Regul. Integr. Comp. Physiol. Section Abstract Doc Link 10749799 Disease Relevance 0.09 Pain Relevance 0
5 years) in women for whom the potential benefits outweigh the potential risks.1,11 The 5-year cut-off for HT is suggested because most women will experience spontaneous cessation of menopausal symptoms within 5 years of onset.1 Use of HT for longer durations may be appropriate in some women, such as those who judge the benefits of VMS relief to outweigh the potential risks after failing an attempt to discontinue HT, those with continued VMS who are also at high risk for osteoporotic fractures, and those requiring osteoporosis prevention who cannot take alternative therapies.2 Several weeks may be required to determine the efficacy of HT in treating VMS.5 Contraindications to the use of HT include breast or estrogen-sensitive cancers, undiagnosed vaginal bleeding, endometrial hyperplasia, blood clotting disorder, hypertension, liver disease, hypersensitivity to the active or excipient compounds in HT.1
Positive_regulation (required) of VMS in liver associated with coagulation disorder, endometriosis (extended), hypersensitivity, osteoporosis, osteoporotic fractures, liver disease, reprotox - general 3, cancer, hypertension and reprotox - general 1
6) Confidence 0.16 Published 2010 Journal Int J Gen Med Section Body Doc Link PMC2880349 Disease Relevance 1.08 Pain Relevance 0
5 years) in women for whom the potential benefits outweigh the potential risks.1,11 The 5-year cut-off for HT is suggested because most women will experience spontaneous cessation of menopausal symptoms within 5 years of onset.1 Use of HT for longer durations may be appropriate in some women, such as those who judge the benefits of VMS relief to outweigh the potential risks after failing an attempt to discontinue HT, those with continued VMS who are also at high risk for osteoporotic fractures, and those requiring osteoporosis prevention who cannot take alternative therapies.2 Several weeks may be required to determine the efficacy of HT in treating VMS.5 Contraindications to the use of HT include breast or estrogen-sensitive cancers, undiagnosed vaginal bleeding, endometrial hyperplasia, blood clotting disorder, hypertension, liver disease, hypersensitivity to the active or excipient compounds in HT.1
Positive_regulation (continued) of VMS in liver associated with coagulation disorder, endometriosis (extended), hypersensitivity, osteoporosis, osteoporotic fractures, liver disease, reprotox - general 3, cancer, hypertension and reprotox - general 1
7) Confidence 0.16 Published 2010 Journal Int J Gen Med Section Body Doc Link PMC2880349 Disease Relevance 1.03 Pain Relevance 0
The Greene Climacteric Scale scores, focusing on the vasomotor domains of hot flashes and night sweats, also showed a significant improvement in VMS for those women treated with the transdermal estradiol spray.
Positive_regulation (improvement) of VMS in sweats associated with hot flashes and transdermal
8) Confidence 0.16 Published 2010 Journal Int J Gen Med Section Body Doc Link PMC2880349 Disease Relevance 0.54 Pain Relevance 0.15
The selective mu-opioid agonist [D-Ala2,MePhe4,Gly-ol5]enkephalin (DAGO) (10 microM) reduced the short circuit (Isc) and the L-valine induced increase of the transepithelial potential difference and Isc(delta Vms and delta Isc) measured in-vitro in rabbit ileum, with a mechanism antagonized by naloxone (1 microM).
Positive_regulation (increase) of Vms in ileum associated with mu agonist, narcan and enkephalin
9) Confidence 0.06 Published 1989 Journal J. Pharm. Pharmacol. Section Abstract Doc Link 2570860 Disease Relevance 0 Pain Relevance 0.71

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox